24/04/2026
From single-point assistance to full-course disease management empowerment! Peking University Third Hospital, in collaboration with Naton, releases an intelligent agent for pancreatic disease diagnosis and treatment, redefining the value of specialized AI in healthcare.
On March 26, at the "Medical AI Innovation and Development Conference" held during the 2026 Zhongguancun Forum Annual Meeting, the "Intelligent Agent for Pancreatic Disease Diagnosis and Treatment," jointly developed by the Department of General Surgery at Peking University Third Hospital and the scientific team of Beijing Naton Intelligent Technology Co., Ltd., a subsidiary of Naton Group, was officially launched.
The successful launch of this intelligent agent is supported by the National Science and Technology Major Project on "Four Major Chronic Diseases" and is the result of collaboration among the Xueyuan Road Alliance, the Innovation and Transformation Center of Peking University Third Hospital, and Beijing Naton Intelligent Technology Co., Ltd. The transition from a "single-point model" to a "full-course intelligent agent" marks a new stage in which AI empowers the prevention and control of major chronic diseases, accelerating the move toward refined, personalized, and full-cycle management.
Pancreatic diseases, especially pancreatic tumors, are characterized by insidious onset, rapid progression, and high diagnostic and therapeutic difficulty, making them a key focus in clinical and research fields. With the rapid updating of medical knowledge and continuous iteration of diagnostic and treatment technologies, there is an increasing clinical demand for precise, standardized, and integrated assistive tools. Traditional fragmented AI tools can no longer meet the needs of full-course disease management.
The newly released intelligent agent for pancreatic disease diagnosis and treatment is designed precisely to address this clinical challenge. Led by Peking University Third Hospital, and in collaboration with the Xueyuan Road Alliance, the Innovation and Transformation Center, and Beijing Naton Intelligent Technology Co., Ltd., the project has formed a closed-loop co-development system. It deeply integrates multidimensional core data, including clinical records, medical images, pathological data, and authoritative diagnosis and treatment guidelines. Using knowledge graphs and large language models, the system builds a specialized intelligent system that forms a complete technical closed loop from preoperative planning, intraoperative support, to postoperative management, providing reliable support for standardized diagnosis and treatment of pancreatic diseases.
Leveraging the strong clinical strength and research translation capabilities of Peking University Third Hospital, as well as the robust AI research and development capabilities of Beijing Naton Intelligent Technology Co., Ltd., the intelligent agent has been refined through real-world clinical scenarios. Its technical architecture and functional design are closely aligned with actual diagnostic and treatment processes, laying a solid foundation for subsequent large-scale application.
The system architecture of the intelligent agent consists of four layers: the medical data layer, the AI capability layer, the clinical agent layer, and the physician interaction layer, covering the entire chain of preoperative, intraoperative, postoperative, and research processes. In terms of technical advantages, the intelligent agent achieves second-level governance of full-chain multimodal data, builds a vertical large language model and retrieval-augmented generation architecture, and leverages deep learning to enable dynamic prognostic simulation and full-cycle intelligent closed-loop management.
With this release, all parties involved will further promote the deployment and scaling of specialized intelligent diagnosis and treatment technologies, bringing advanced AI solutions to more patients with pancreatic diseases.